CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "GLUTATHIONE FOR INJECTION"

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC Pharmaceutical Group Limited

石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF

THE GROUP'S "GLUTATHIONE FOR INJECTION"

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that "Glutathione for Injection (0.3g)" (the "Product") developed by CSPC Ouyi Pharmaceutical Co. Ltd.*（石藥集團歐意藥業 有限公司）, a subsidiary of the Group, has been granted drug registration approval by the National Medical Products Administration of the People's Republic of China.

Glutathione is a tripeptide containing sulfhydryl (SH) which exists in abundance in nature, playing a role in various cellular biochemical functions and involved in in-vivo tricarboxylic acid cycle and glucose metabolism. It facilitates the metabolism of carbohydrate, fat and protein, and also facilitates the formation of easy-metabolized compounds of low toxicity, having a detoxification effect on certain exogenous toxic substances. It can be used for patients undergoing chemotherapy (especially in high-dose chemotherapy) or radiotherapy, hypoxemia, liver diseases (including liver damage caused by virus and drug toxicity), adjuvant treatment for organophosphorus or nitro compound intoxication, and drug detoxification.

Glutathione for injection is one of the Group's products for the treatment of liver diseases. The approval of the Product will enhance the Group's product lines and provide patients with a better medication option.

• for identification purpose only

- 1 -

By Order of the Board

CSPC Pharmaceutical Group Limited

CAI Dongchen

Chairman

Hong Kong, 26 September 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

- 2 -